CoChat
Sign Up
Cited by 52Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot

Open access
Treloar, Carla, Lancaster, Kari, Gendera, Sandra, Rhodes, Tim, Shahbazi, Jeyran, Byrne, Marianne, Degenhardt, Louisa, Farrell, Michael·2022·International Journal of Drug Policy
DOI 10.1016/j.drugpo.2022.103788
Open this paper in CoChat — free account

Abstract

Introduction Stigma has corrosive effects on all aspects of care and can undermine individual and population health outcomes. Addiction-related stigma has implications for opiate agonist treatment (OAT) and the people who receive, provide and fund it. It is important to understand how stigma is made in OAT and the political purposes that it serves, in order to change the relations of stigma and avoid the reproduction of stigma in the delivery of new treatment formulations, such as extended release buprenorphine (BUP-XR). Methods Semi-structured qualitative interviews were conducted at two time points with participants in a prospective single-arm, multicentre, open-label trial of monthly BUP-XR. Thirty-six participants (25 men, 11 women) were interviewed, and of these 32 participated in a second interview to explore their experience of transition from other treatment to BUP-XR. Results Participants were highly aware of the of the social and material effects of stigma through the negative stereotypes attached to OAT and those who receive it. Participants narrated examples of how stigma governed as a biopower in the relations and practices of OAT provision at numerous levels: structural (such as in public discourse about OAT and the people who receive it, in media, in perceptions about the decisions of investment in medical technologies); organisational (policies about legitimate access to OAT); interpersonal (with health workers) and individual (self-identities). BUP-XR allowed…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.drugpo.2022.103788

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Qualitative research suggests notable benefits associated with extended-release buprenorphine, including a decrease in stigma, ability to lead a "normal life," and increased convenience.

    “Nevertheless, qualitative research suggests some notable benefits associated with extended-release buprenorphine, including a decrease in stigma, ability to lead a “normal life,” and increased convenience.14,15”

    From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [14]

  • These factors suggest a potential for improved retention on extended-release buprenorphine for later adopters.

    “These factors all suggest a potential for improved retention on extended-release buprenorphine for later adopters.14,15”

    From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [14]

  • Extended-release buprenorphine may decrease stigma that is associated with daily dosing of medication.

    “Extended-release buprenorphine may decrease stigma that is associated with daily dosing of medication.14”

    From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [14]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. Barnett, 2021, Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia, Drug and Alcohol Dependence, 227, 10.1016/j.drugalcdep.2021.108959 · DOI
  2. Bourgois, 2000, Disciplining addictions: The biopolitics of methadone and heroin in the United States, Culture, Medicine and Psychiatry, 24, 165, 10.1023/A:1005574918294 · DOI
  3. Brener, 2009, Exploring the role of consumer participation in drug treatment, Drug and Alcohol Dependence, 105, 172, 10.1016/j.drugalcdep.2009.06.016 · DOI
  4. Collins, 2016, Navigating identity, territorial stigma, and HIV care services in Vancouver, Canada: A qualitative study, Health & Place, 40, 169, 10.1016/j.healthplace.2016.06.005 · DOI
  5. Crawford, 2013, Shouting through bullet-proof glass: Some reflections on pharmacotherapy provision in one Australian clinic, International Journal of Drug Policy, 24, e14, 10.1016/j.drugpo.2013.07.004 · DOI
  6. Earnshaw, 2013, Drug addiction stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma, International Journal of Mental Health and Addiction, 11, 110, 10.1007/s11469-012-9402-5 · DOI
  7. Farrell, 2021, Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence, International Journal of Drug Policy, 100
  8. Fraser, 2017, Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis, International Journal of Drug Policy, 44, 192, 10.1016/j.drugpo.2017.02.005 · DOI
  9. Fraser, 2020, Exclusion and hospitality: The subtle dynamics of stigma in healthcare access for people emerging from alcohol and other drug treatment, Sociology of Health & Illness, 42, 1801, 10.1111/1467-9566.13180 · DOI
  10. Fraser, 2006, Speaking addictions: substitution, metaphor and authenticity in newspaper representations of methadone treatment, Contemporary Drug Problems, 33, 669, 10.1177/009145090603300406 · DOI
  11. Fraser, 2006, The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects, International Journal of Drug Policy, 17, 192, 10.1016/j.drugpo.2006.02.010 · DOI
  12. Frost, 2019, Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder, Addiction, 114, 1416, 10.1111/add.14636 · DOI
  13. Gomart, 2002, Towards generous constraint: Freedom and coercion in a French addiction treatment, Sociology of Health & Illness, 24, 517, 10.1111/1467-9566.00307 · DOI
  14. Harris, 2012, Methadone as social control: Institutionalized stigma and the prospect of recovery, Qualitative Health Research, 22, 810, 10.1177/1049732311432718 · DOI
  15. Harris, 2021, Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research, International Journal of Drug Policy, 96, 10.1016/j.drugpo.2021.103320 · DOI
  16. Harris, 2015, To be free and normal: Addiction, governance, and the therapeutics of buprenorphine, Medical Anthropology Quarterly, 29, 512, 10.1111/maq.12232 · DOI
  17. Järvinen, 2010, Methadone maintenance as last resort: A social phenomenology of a drug policy, Sociological Forum, 25, 804, 10.1111/j.1573-7861.2010.01213.x · DOI
  18. Keane, 2009, Foucault on methadone: Beyond biopower, International Journal of Drug Policy, 20, 450, 10.1016/j.drugpo.2008.10.005 · DOI
  19. Lancaster, 2015, Stigma and subjectivities: Examining the textured relationship between lived experience and opinions about drug policy among people who inject drugs, Drugs: Education, Prevention and Policy., 22, 224
  20. Lancaster, K., Gendera, S., Treloar, C., Rhodes, T., Shahbazi, J., Byrne, M., Degenhardt, L. & Farrell, M. (2021) Experiences and effects of extended-release buprenorphine depot treatment: Qualitative findings from the CoLAB study, Drug and Alcohol Review, 40 (Suppl. 1), S18.
  21. Larance, 2020, Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study, BMJ Open, 10, 10.1136/bmjopen-2019-034389 · DOI
  22. Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 2020b;115(7):1295-305. · DOI
  23. Ling, 2020, Recovery From Opioid Use Disorder (OUD) after monthly long-acting buprenorphine treatment: 12-Month longitudinal outcomes from RECOVER, an Observational study, Journal of Addiction Medicine, 14, e233, 10.1097/ADM.0000000000000647 · DOI
  24. Link, 2001, Conceptualizing stigma, Annual Review of Sociology, 27, 363, 10.1146/annurev.soc.27.1.363 · DOI · Paper page
  25. Lintzeris, 2021, Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial, JAMA Network Open, 4, 10.1001/jamanetworkopen.2021.9041 · DOI
  26. Lloyd, 2013, The stigmatization of problem drug users: A narrative literature review, Drugs: Education, Prevention & Policy, 20, 85
  27. Lofwall, 2018, Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial, JAMA Internal Medicine, 178, 764, 10.1001/jamainternmed.2018.1052 · DOI
  28. Matthew-Simmons, 2014, Miracle cure' or 'liquid handcuffs': Reporting on naltrexone and methadone in the Australian print media, Drug and Alcohol Review, 33, 506, 10.1111/dar.12134 · DOI
  29. Mattick, 2014, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002207.pub4 · DOI
  30. McLeroy, 1988, An ecological perspective on health promotion programs, Health Education Quarterly, 15, 351, 10.1177/109019818801500401 · DOI · Paper page
  31. Neale, 2018, Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin, Drug and Alcohol Dependence, 189, 1, 10.1016/j.drugalcdep.2018.03.057 · DOI
  32. Neale, 2019, Prolonged-release opioid agonist therapy: Qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations, Harm Reduction Journal, 16, 25, 10.1186/s12954-019-0296-4 · DOI
  33. Nguyen, 2019, Struggling to achieve a ‘normal life’: A qualitative study of Vietnamese methadone patients, International Journal of Drug Policy, 68, 18, 10.1016/j.drugpo.2019.03.026 · DOI
  34. Nyblade, 2019, Stigma in health facilities: Why it matters and how we can change it, BMC Medicine, 17, 25, 10.1186/s12916-019-1256-2 · DOI · Paper page
  35. Nyblade, 2021, Stigma reduction: An essential ingredient to ending AIDS by 2030, The Lancet HIV, 8, e106, 10.1016/S2352-3018(20)30309-X · DOI
  36. Parida, 2019, Buprenorphine treatment for opioid use disorder: Recent progress, Expert Review of Clinical Pharmacology, 12, 791, 10.1080/17512433.2019.1635454 · DOI
  37. Parsons, 2020, Patient-reported outcomes, experiences and satisfaction with weekly and monthly injectable prolonged-release buprenorphine, Substance Abuse and Rehabilitation, 11, 41, 10.2147/SAR.S266838 · DOI
  38. Pienaar, 2015, New narratives, new selves: Complicating addiction in online alcohol and other drug resources, Addiction Research and Theory, 23, 499, 10.3109/16066359.2015.1040002 · DOI
  39. Rhodes, 2013, Negotiating access to medical treatment and the making of patient citizenship: The case of hepatitis C treatment, Sociology of Health & Illness, 35, 1023, 10.1111/1467-9566.12018 · DOI
  40. Rhodes, 2019, The becoming-methadone-body: On the onto-politics of health intervention translations, Sociology of Health & Illness, 41, 1618, 10.1111/1467-9566.12978 · DOI
  41. Rhodes, 2018, The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential, Social Science & Medicine, 201, 71, 10.1016/j.socscimed.2018.02.007 · DOI
  42. Salmon, 2007, Five years on: What are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre?, International Journal of Drug Policy, 18, 46, 10.1016/j.drugpo.2006.11.010 · DOI
  43. Seear, 2017, A new framework for evaluating the potential for drug law to produce stigma: Insights from an Australian study, Journal of Law, Medicine and Ethics, 45, 596, 10.1177/1073110517750599 · DOI
  44. Smith, 2011, A users’ guide to ‘juice bars’ and ‘liquid handcuffs’: Fluid negotiations of subjectivity, space and the substance of methadone, Space and Culture, 14, 291, 10.1177/1206331211412238 · DOI
  45. Strike, 2004, Finding a place for needle exchange programs, Critical Public Health, 14, 261, 10.1080/09581590400004386 · DOI
  46. Takahashi, 1997, The socio-spatial stigmatization of homelessness and HIV/AIDS: Toward an explanation of the NIMBY syndrome, Social Science & Medicine, 45, 903, 10.1016/S0277-9536(96)00432-7 · DOI
  47. Treloar, 2013, Examining structural violence in methadone maintenance treatment in Australia: Sweating the "small stuff" in a liberal paradise, International Journal of Drug Policy, 24, e11, 10.1016/j.drugpo.2013.04.010 · DOI
  48. Treloar, 2015, ‘Doing the devil's work’: Emotional labour and stigma in expanding Needle and Syringe Programs, Drugs: Education, Prevention and Policy, 22, 437
  49. Valentine, 2007, Methadone maintenance treatment and making up people, Sociology, 41, 497, 10.1177/0038038507076619 · DOI
  50. Vrecko, 2010, Civilizing technologies’ and the control of deviance, BioSocieties, 5, 36, 10.1057/biosoc.2009.8 · DOI
  51. Weinberg, 2000, Out there": The ecology of addiction in drug abuse treatment discourse, Social Problems, 47, 606, 10.2307/3097137 · DOI
  52. Wolfe, 2021, Biotechnologies and the future of opioid addiction treatments, International Journal of Drug Policy, 88, 10.1016/j.drugpo.2020.103041 · DOI

Cited by

Sorted by citations

Metadata

Authors
Treloar, C., Lancaster, K., Gendera, S., Rhodes, T., Shahbazi, J., Byrne, M., Degenhardt, L., & Farrell, M.
Affiliations
UNSW Sydney (AU)
Corresponding author
Treloar, Carla
ORCID
Venue
International Journal of Drug Policy
Publisher
Elsevier BV
Published
2022-09
Volume
107
Pages
103788
ISSN
0955-3959 (ISSN-L)
DOI
10.1016/j.drugpo.2022.103788
OpenAlex
W4284963955
Cited by
52
References
4
Citations by year
2026: 5 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 1
FWCI
10.37
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Drug Policy (acceptedVersion)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
extended-release buprenorphine, biopolitics, biopower, self-identity, treatment transition, opioid use disorder
MeSH terms
Analgesics, Opioid, Buprenorphine, Delayed-Action Preparations, Female, Humans, Male, Narcotic Antagonists, Opioid-Related Disorders, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review